A new chemical approach to human ABO Histo-Blood group Type 2 antigens

Article abstract of DOI:10.3390/molecules19010414

A new chemical approach to synthesizing human ABO histo-blood type 2 antigenic determinants was developed. N-Phthaloyl-protected lactosaminyl thioglycoside derived from lactulose via the Heyns rearrangement was employed to obtain a type 2 core disaccharide. Use of this scheme lowered the overall number of reaction steps. Stereoselective construction of the a-galactosaminide/galactoside found in A- and B-Antigens, respectively, was achieved by using a unique di-tert-butylsilylene-directed a-glycosylation method. The proposed synthetic scheme provides an alternative to existing procedures for preparing ABO blood group antigens.

Full text of DOI:10.3390/molecules19010414

Molecules 2014, 19, 414-437; doi:10.3390/molecules19010414
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
A New Chemical Approach to Human ABO Histo-Blood Group
Type 2 Antigens
Atsushi Hara 1, Akihiro Imamura 1,*, Hiromune Ando 1,2, Hideharu Ishida 1 and
Makoto Kiso 1,2,
*
1
Department of Applied Bioorganic Chemistry, Faculty of Applied Biological Sciences,
Gifu University, 1-1 Yanagido, Gifu-shi, Gifu 501-1193, Japan;
E-Mails: r8101036@edu.gifu-u.ac.jp (A.H.); hando@gifu-u.ac.jp (H.A.); ishida@gifu-u.ac.jp (H.I.)
Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University, Yoshida
Ushinomiya-cho, Sakyo-ku, Kyoto 606-8501, Japan
2
* Authors to whom correspondence should be addressed; E-Mails: aimamura@gifu-u.ac.jp (A.I.);
kiso@gifu-u.ac.jp (M.K.); Tel.: +81-58-293-3453 (A.I.); Fax: +81-58-293-2918 (M.K.).
Received: 13 December 2013; in revised form: 24 December 2013 / Accepted: 25 December 2013 /
Published: 31 December 2013
Abstract: A new chemical approach to synthesizing human ABO histo-blood type 2
antigenic determinants was developed. N-Phthaloyl-protected lactosaminyl thioglycoside
derived from lactulose via the Heyns rearrangement was employed to obtain a type 2 core
disaccharide. Use of this scheme lowered the overall number of reaction steps.
Stereoselective construction of the α-galactosaminide/galactoside found in A- and
B-antigens, respectively, was achieved by using a unique di-tert-butylsilylene-directed
α-glycosylation method. The proposed synthetic scheme provides an alternative to existing
procedures for preparing ABO blood group antigens.
Keywords: blood group antigen; oligosaccharide; glycosylation; Heyns rearrangement
1. Introduction
ABO histo-blood group antigens are expressed on red blood cells and are widely distributed in
various tissues such as the vascular endothelium, where they are displayed on plasmalemmal
glycoproteins and glycolipids by attachment to sugar residues that terminate N-linked, O-linked, and
lipid-linked glycans [1,2]. The A, B, and O group antigens are defined by the GalNAcα(1-3)[Fucα(1-

Molecules 2014, 19
415
2)]Gal, Galα(1-3)[Fucα(1-2)]Gal, and Fucα(1-2)Gal glycan structures, respectively. These antigens
can be further divided into six subtypes based on linkage arrangement: type 1, ABO-β(1-3)GlcNAcβ;
type 2, ABO-β(1-4)GlcNAcβ; type 3, ABO-β(1-4)GalNAcα; type 4, ABO-β(1-3)GalNAcβ; type 5,
ABO-β(1-3)Galβ; and type 6: ABO-β(1-4)Glcβ[3,4]. Since the discovery of ABO antigens over a
century ago [5], many biological phenomena associated with them have been found, for example:
immune response in blood transfusion and organ transplantation [6,7]; susceptibility to certain diseases
in individuals with a particular ABO phenotype [8–10]; function as a receptor for pathogens such as
Campylobacter jejuni [11], Helicobacter pylori [12], and Norwalk virus [13,14]; and aberrant
expression in the oncogenesis of various organs [15,16]. However, little progress has been made in
elucidating their physiological behavior at the molecular level because of a lack of pure materials for
scientific research. We envisioned that chemically synthesized pure samples would enable a range of
studies on the physiological and pathological implications of ABO group antigens. The chemical
synthesis of type 1 glycans has been reported by several groups [4,17–23], but reports on the synthesis
of type 2 glycans have been limited [4,24–26]. Also, it should be noted that synthetic studies of ABO
antigens were first reported by Lemieux's group and they then focused on Lewis antigens [27–31]. The
goal of our research is therefore to develop a facile synthetic route to ABO histo-blood group antigens,
particularly type 2 glycans. Here we describe a new chemical approach to ABO group type 2 antigens
with a pentylamine linker (1‒3; Figure 1), which are expected to be useful in future biological studies.
Figure 1. Structure of the target ABO blood-group type 2 antigens.
HO
HO
HO
HO
OH
O
OH
O
HO
HO
OH
O
OH
O
NHAc
O
NHAc
O
AcHN
HO
HO
HO
O
O
NH2
NH2
O
O
O
O
O
O
OH
OH
O
O
OH
OH
1
2
OH
HO
OH
HO
(A determinant)
(B determinant)
HO
HO
OH
O
NHAc
HO
O
NH2
O
O
O
OH
O
OH
3
OH
HO
(O determinant)
2. Results and Discussion
The typical procedure for synthesizing ABO blood group antigens is stepwise assembly of the
monosaccharide unit, which requires a laborious protection/deprotection strategy for the multistep
preparation of both monosaccharide donor and acceptor. To improve accessibility to those antigens, we
designed a unique synthetic route to the target ABO group type 2 antigenic oligosaccharides. As
shown in Scheme 1, our synthetic strategy involves two key reactions: (1) the Heyns rearrangement for
simple preparation of N-acetyl-lactosamine (4-O-β-D-galactopyranosyl-D-N-acetyl-glucosamine), a

Molecules 2014, 19
416
type 2 core disaccharide; and (2) di-tert-butylsilylene (DTBS)-directed α-galactosaminylation and
α-galactosylation for the formation of A and B determinants, respectively.
Scheme 1. Retrosynthetic analysis of target compounds.
HO
RO
OH
O
NHAc
O
HO
NH2
O
O
O
OH
O
1: R = -GalNAc
2: R = -Gal
3: R = H
OH
OH
HO
DTBS-directed -glycosylation
DTBS
PO
HO
OP
O
NPhth
O
PO
NHCbz
O
Si
O
5
O
+
O
O
OP
O
O
SPh
PO
OP
X = NHP (for 1)
X = OP (for 2)
common trisaccharide
X
OP
PO
L
PO
OP
O
NPhth
SEt
O
PO
O
OP
PO
+
O
OP
PO
OH
OP
Heyns rearrangement
P: protecting group
L: leaving group
HO
OH
O
OH
OH
HO
HO
OH
O
O
OH
The Heyns rearrangement is known to be effective for obtaining a lactosamine derivative by simple
manipulation starting from lactulose (4-O-β-D-galactopyranosyl-D-fructose). This reaction was
originally developed for converting ketoses into the corresponding 2-amino-2-deoxyaldoses [32]. We
hoped that the use of lactulose (4) as an alternate starting material would allow us to minimize the
number of reaction steps as well as to reduce the time and effort needed. Additionally, lactulose is a
relatively inexpensive and commercially available sugar. Recently, Wrodnigg and co-workers reported
an improved Heyns rearrangement procedure, which was much more practical than the original
procedure [33,34]. Other groups have recently reported even more practical protocols suitable for
large-scale synthesis [35,36]. In the present study, we followed these procedures to obtain lactosamine
derivative 5 [37] as a key building block. Compound 5 was efficiently prepared in five steps (Scheme 2)

Molecules 2014, 19
417
by methods in the literature [33–36]. Conversion of peracetate derivative 5 into thioglycoside form
was performed in the presence of ethanethiol and BF3·OEt2 in 1,2-dichloroethane to give
ethylthioglycoside 6 in 96% yield. The ethylsulfinyl group was selected in consideration of its
solubility in MeOH, which was used in the next step. A phenylsulfinyl group in place of the
ethylsulfinyl group resulted in poor solubility in MeOH, leading to a poor results in the deacetylation
reaction. After removal of all acetyl groups in 6, hydroxyl groups at the C2 and C3 positions of the
galactose residue were simultaneously protected as a butanediacetal (BDA) [38] to afford compound 8.
In this reaction, a regioisomer of 8, namely, a 3,4-O-BDA-protected by-product, was formed and these
regioisomers were separated by silica gel column chromatography. However, small amounts of
impurities could not be separated from 8. Acetylation of 8 along with contaminants and subsequent
hydrolysis of the BDA group afforded diol 10 as the sole product in 57% yield over the four
operations. The tin-mediated selective acylation developed by Muramatsu [39] was then applied to
selectively protect the C3′-OH group by the Troc group, giving the disaccharide acceptor 11 in 84%
yield. Another procedure for selective protection of the C3′-OH group by treatment of TrocCl with
pyridine in CH2Cl2 at lower temperature (−40 °C) gave 11 in somewhat lower yield (76%). For next
glycosylation, the fucosyl N-phenyltrifluoroacetimidate 12 was designed to increase both reactivity
and stability as a fucose donor. The previously used fucosyl donor, 2,3,4-tri-O-benzyl-protected
fucosyl imidate, could be served as a good fucosyl donor, but was relatively unstable under
glycosylation conditions due to its armed feature. Chemo-selectively removable PMB group was
chosen as a protecting group at C2 position and electron-withdrawing acetyl groups at C3 and C4 were
incorporated to suppress the armed feature by the PMB group, which could lead to stabilization of the
donor. Furthermore, a more stable N-phenyltrifluoroacetimidate group compared to a trichloroacetimidate
group was used as a leaving group [40,41]. The glycosylation of 11 with 12, which was derived from a
known fucose derivative [42] and was promoted by TMSOTf in a mixed solvent system of
cyclopentylmethyl ether (CPME)–dichloromethane (1:1) [43] at −80 °C, provided trisaccharide 13.
Small amounts of contaminates remained after column chromatography. The mixture containing
contaminants was used directly in the next reaction. Removal of the p-methoxybenzyl (PMB) group
under acidic conditions allowed for purification of the newly formed trisaccharide, affording 14 with a
yield of 88% over two steps. Acetylation of the liberated hydroxyl group afforded compound 15 with a
yield of 95%. Next, the coupling reaction of 15 with N-Cbz-protected aminopentanol 16 occurred
smoothly in the presence of N-iodosuccinimide (NIS) and TfOH [44,45] in CH2Cl2 at 0 °C to give the
desired glycoside 17 in 85% yield. Subsequent deprotection of the Troc group by treatment with zinc
and AcOH [46] in 1,2-dichloroethane at 40 °C afforded common trisaccharide derivative 18 with a
yield of 90%.
For constructing the A and B antigen skeletons, it is necessary to incorporate galactosamine
(for A antigen) and galactose (for B antigen) residues into trisaccharide 18 in α-linked form. Typically,
α-D-galactosides are obtained by using ethereal solvents such as diethyl ether and 1,4-dioxane as well
as the anomeric effect [47].

Molecules 2014, 19
418
Scheme 2. Synthesis of the common trisaccharide unit.
HO
EtSH
BF3·OEt2
OH
AcO
AcO
AcO
AcO
O
OAc
O
OAc
O
NPhth
OAc
NPhth
OH
OH
5 steps
HO
OH
O
AcO
O
AcO
SEt
O
O
O
(CH2Cl)2
r. t.
96%
Refs. 33–36
HO
O
OAc
OAc
OAc
OAc
OH
4
5
6
2,3-butanedione
CSA
(MeO)3CH
OH
O
HO
MeO
O
HO
HO
NPhth
Ac2O
DMAP
OH
O
NPhth
NaOMe
HO
SEt
HO
O
SEt
O
O
O
O
MeOH–DCM
(2:1)
MeOH
reflux
OH
Py
r. t.
OH
OH
MeO
7
8
r. t.
TrocCl
Bu2SnCl2
PEMP
OAc
AcO
MeO
AcO
AcO
TrocO
OAc
O
OAc
O
NPhth
SEt
NPhth
NPhth
90% TFA aq.
O
AcO
AcO
O
AcO
O
SEt
SEt
HO
O
O
O
O
O
acetone
10 °C
84%
O
r. t.
57%
(over 4 steps)
OAc
OH
OH
OAc
OAc
MeO
9
10
11
NPh
CF3
O
O
AcO
TrocO
AcO
TrocO
OAc
O
OAc
O
AcO
NPhth
NPhth
OPMB
HO
NHCbz
16
AcO
O
OAc
SEt
SEt
O
12
AcO
O
O
NIS
TfOH
O
O
OAc
OAc
TMSOTf
Ac2O
O
O
OR
OAc
MS AW-300
CPME–DCM
(1:1)
Py
r. t.
95%
MS 4Å
DCM
0 °C
OAc
AcO
OAc
AcO
15
–80 °C
85%
13: R = PMB
14: R = H
TFA, CH2Cl2, r. t.
88% (2 steps)
AcO
AcO
HO
OAc
O
OAc
O
Zn
AcOH
NPhth
NPhth
AcO
AcO
O
O
O
NHCbz
NHCbz
TrocO
O
5
O
O
(CH2Cl)2
40 °C
90%
O
O
OAc
OAc
O
O
OAc
OAc
OAc
AcO
OAc
AcO
17
18
However, highly α-selectivity in such galactosylation is generally difficult and strongly dependent
on various factors, such as the substrate structure, promoter, and temperature. The stereoisomers
formed are often difficult to separate, which presents a serious disadvantage for synthetic studies. In
2003, we developed a reliable method for α-selective galactosidation andgalactosaminidation using
DTBS-protected glycosyl donors [48–51]. Notable features of the DTBS-directed α-galactosylation are
excellent α-selectivity even in the presence of a neighboring participating group on the C2 oxygen or
nitrogen, and the relatively greater difference between the Rf values of the α and β isomers that enables
them to be more easily separated. Thus, we decided to utilize DTBS-directed α-galactosylation for the
construction of the A and B antigen sequences.
As shown in Scheme 3, trisaccharide acceptor 18 was glycosylated with galactosaminyl donor 19 [48]
and galactosyl donor 20 [52] in the presence of NIS and TfOH in CH2Cl2 at 0 °C, giving the
corresponding tetrasaccharides 21 and 22 in α-linked form in yields of 82% and 58%, respectively. In
these reactions, the recovery of unreacted acceptor 18 was 9% and 22%, when 19 and 20 were used,

Molecules 2014, 19
419
respectively, despite the use of 2 equiv of donor. However, other possible stereoisomers were not
detected and both α-products were easy to isolate by column chromatography. To our surprise, the
coupling yield of 22 was moderate. When we attempted to use the armed 2,3-di-O-benzyl-type
galactose donor instead of 20, the yield was not improved (41%) and many unidentified by-products
were generated. The unexpectedly low reactivity of 18 as a glycosyl acceptor might arise from steric
hindrance around 3-OH on the Gal residue.
Scheme 3. Assembly of A and B antigen sequences.
Si
O
Si
O
Si
O
O
O
O
O
O
O
R2
TrocO
BnO
or
SPh
NHTroc
SPh
OBz
AcO
OAc
O
NPhth
O
R1
AcO
O
O
NHCbz
19
20
5
O
NIS
O
OAc
TfOH
O
18
OAc
MS 4Å
DCM
0 °C
OAc
AcO
21: R1 = NHTroc, R2 = OTroc (82%)
22: R1 = OBz, R2 = OBn (58%)
Scheme 4. Global deprotection sequence.
Si
O
HO
HO
O
OH
O
AcO
AcO
OAc
O
O
HO
OH
O
R2O
NHAc
O
AcO
AcHN
b
c
d
OAc
O
NPhth
O
HO
O
R1
O
NHCbz
1
5
AcO
AcHN
O
96%
O
NHCbz
80%
98%
O
O
5
O
O
OH
O
OAc
24
O
OH
O
21: R1 = NHTroc, R2 = Troc
23: R1 = NHAc, R2 = H
OAc
OH
HO
25
a
OAc
AcO
84%
Si
O
HO
O
OH
O
AcO
BnO
OAc
O
BnO
O
HO
OH
O
NHAc
BnO
AcO
e
HO
b
c
OAc
O
NPhth
HO
O
O
O
NHCbz
2
BzO
5
AcO
O
O
BzO
O
O
NHCbz
81%
99%
quant.
O
5
O
O
OH
O
OAc
26
O
OH
O
OAc
OH
HO
22
27
OAc
AcO
AcO
HO
HO
HO
OAc
O
OH
O
NPhth
O
NHAc
AcO
O
HO
O
O
NHCbz
NHCbz
5
c
d
5
O
O
3
O
O
OAc
OH
94%
73%
O
O
OAc
OH
OAc
AcO
OH
HO
18
28
Reagents and conditions: (a) (i) Zn, AcOH, (CH2Cl)2, 40 °C, (ii) Ac2O, MeOH, r.t.; (b) (i) TBAHF, THF, r.t.
(ii) Ac2O, Py, r.t.; (c) (i) NH2NH2·H2O, EtOH, reflux, (ii) Ac2O, MeOH, r.t.; (d) H2, Pd/C, MeOH–H2O (1:1),
r.t.; (e) H2, Pd/C, 1,4-dioxane–2% aq. formic acid (1:1), r.t.

Molecules 2014, 19
420
On the route to the target compounds, there is a global deprotection sequence (Scheme 4). Selective
removal of the Troc groups of 21 by treatment with zinc and AcOH, followed by selective acetylation
of the liberated amine of the galactosamine residue at C2 afforded 23 in 84% yield. Then, removal of
the DTBS group with tributylamine hydrofluoride (TBAHF) in THF [53] followed by acetylation of
the hydroxyl groups provided 24 in 98% yield over two steps. After removal of all acetyl groups on 24,
the phthalimide group at C2 of the glucosamine residue was converted to an acetamide group by
sequential treatment with hydrazine hydrate in refluxing EtOH followed by selective acetylation of the
free amine, affording 25 in 80% yield over three steps. Finally, the Cbz group at the terminus of the
linker was removed by hydrogenolysis with Pd/C under hydrogen atmosphere, thus furnishing target 1
(A antigen) in 81% yield. Similarly, the deprotection of compounds 22 and 18 were efficiently carried
out to furnish target compounds 2 (B antigen) and 3 (O antigen) in good yields.
3. Experimental
3.1. General Methods
All reactions were carried out under a positive pressure of argon, unless otherwise noted. All
chemicals were purchased from commercial suppliers and used without further purification, unless
otherwise noted. Molecular sieves were purchased from Nacalai Tesque, Inc. (Kyoto, Japan) and dried
at 300 °C for 12 h in a muffle furnace prior to use. Solvents as reaction media such as CH2Cl2, MeOH,
THF, DMF, and pyridine, which were tapped off from The Solvent Supply System, were purchased
from Kanto Chemical Co., Inc. (Tokyo, Japan) and used without purification. TLC analysis was
performed on Merck TLC (silica gel 60F254 on glass plate, Darmstadt, Germany). Compound
detection was either by exposure to UV light (2536 Å) or by soak in a solution of 10% H2SO4 in
ethanol followed by heating. Silica gel (80 mesh and 300 mesh) manufactured by Fuji Silysia
Chemical Ltd. (Kasugai, Japan) was used for flash column chromatography. Quantity of silica gel was
usually estimated as 100 to 200-fold weight of sample to be charged. Solvent systems in
chromatography were specified in v/v. Evaporation and concentration were carried out in vacuo. 1H-NMR
and 13C-NMR spectra were recorded with Bruker Biospin AVANCE III 500/800 spectrometers
1
(Billerica, MA, USA). Chemical shifts in H-NMR spectra are expressed in ppm (δ) relative to the
signal of Me4Si, adjusted to δ 0.00 ppm. Data are presented as follow: Chemical shift, multiplicity
(s = singlet, d = doublet, t = triplet, dd = double of doublet, td = triple doublet, m = multiplet and/or
multiple resonances), integration, coupling constant in Hertz (Hz), position of the corresponding
proton. COSY methods were used to confirm the NMR peak assignments. High-resolution mass
(ESI-TOF MS) spectra were run in a Bruker Daltonics micrOTOF (Billerica, MA, USA). Optical
rotations were measured with a ‘Horiba SEPA-300’ high-sensitive polarimeter (Kyoto, Japan).
3.2. Physical Data for All New Compounds
AcO
AcO
OAc
O
NPhth
SEt
AcO
O
O
OAc
OAc

Molecules 2014, 19
421
Ethyl (2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-(1→4)-3,6-di-O-acetyl-2-deoxy-2-phthalimide-1-
thio-β-D-glucopyranoside (6). To a mixture of 5 (4.16 g, 5.44 mmol) in (CH2Cl)2 (27.2 mL) were
added EtSH (606 µL, 8.16 mmol) and BF3·OEt2 (1.03 mL, 8.16 mmol) at 0 °C. After stirring for 2 h at
rt as the reaction was monitored by TLC (3:2 EtOAc–hexane), the reaction was quenched by the
addition of crushed ice. The solution was diluted with CHCl3 and subsequently washed with ice-cooled
H2O, satd aq Na2CO3, and brine. The organic layer was then dried over Na2SO4, and concentrated. The
resulting residue was purified by silica gel column chromatography (1:1 EtOAc–hexane) to give 6
(3.99 g, 96%). Spectroscopic data of 6 were identical to those reported in the literature [54].
AcO
HO
OAc
O AcO
NPhth
SEt
O
O
OH
OAc
Ethyl (4,6-di-O-acetyl-β-D-galactopyranosyl)-(1→4)-3,6-di-O-acetyl-2-deoxy-2-phthalimide-1-thio-β-
D-glucopyranoside (10). To a solution of 6 (1.08 g, 1.41 mmol) in MeOH/CH2Cl2 (2:1, 14.1 mL) was
added NaOMe (28% solution in MeOH, 31.9 µL, 141 µmol) at 0 °C. After stirring for 2 h at rt as the
reaction was monitored by TLC (3:2 EtOAc–hexane), the reaction was neutralized with AcOH. After
concentration, the resulting residue was diluted with CHCl3 and subsequently washed with H2O and
brine. The organic layer was dried over Na2SO4, of which solid was filtered through cotton and the
filtrate was then evaporated (giving 7). The residue was subjected to next reaction without further
purification. The crude product 7 was dissolved in MeOH (28.2 mL). To the solution were added
2,3-butanedione (492 µL, 5.64 mmol), trimethyl orthoformate (1.95 mL, 17.8 mmol), and
(±)-10-camphorsulfonic acid (66 mg, 282 µmol) at rt. After stirring for 20 h at reflux as the reaction
was monitored by TLC (10:1 CHCl3–MeOH), the reaction was quenched by the addition of
triethylamine (218 µmol) and concentrated. The resulting residue was diluted with CHCl3 and
subsequently washed with H2O and brine. The organic layer was dried over Na2SO4, filtered,
concentrated. The resulting residue was roughly purified by silica gel column chromatography (20:1
CHCl3–MeOH) to give 2,3-O-BDA-protected product 8 along with small amounts of contaminants.
The crude mixture (494 mg) was dissolved in pyridine (7.8 mL). To the solution were added Ac2O
(890 µL, 9.42 mmol) and a catalytic amount of DMAP at 0 °C. After stirring for 1 h at rt as the
reaction was monitored by TLC (3:2 EtOAc–hexane), the mixture was co-evaporated with toluene.
The resulting residue was diluted with EtOAc and subsequently washed with 2 M HCl, H2O, satd aq
NaHCO3, and brine, dried over Na2SO4, and concentrated. The resulting residue was purified by silica
gel column chromatography (2:3 EtOAc–hexane) to give 9 (634 mg), to which suspension in H2O (1.6 mL)
was added trifluoroacetic acid (14.4 mL) at 0 °C. After stirring for 2 h at rt as the reaction was
monitored by TLC (1:1 CHCl3–acetone), the mixture was diluted with toluene and concentrated. The
resulting residue was purified by silica gel column chromatography (7:3 CHCl3–acetone) to give 10
1
(548 mg, 57% over four steps). [α]D +18.3° (c 1.0, CHCl3); H-NMR (500 MHz, CDCl3) δ 7.88–7.74
(m, 4H, Phth), 5.84 (dd, 1H, J3,4 = 8.2 Hz, J2,3 = 11.2 Hz, H-3GlcN), 5.50 (d, 1H, J1,2 = 10.6 Hz,
H-1GlcN), 5.28 (d, 1H, J3,4 = 3.3 Hz, H-4Gal), 4.63 (dd, 1H, J5,6a = 1.6 Hz, Jgem = 11.9 Hz, H-6aGlcN),
4.40–4.29 (m, 3H, H-2GlcN, H-6bGlcN, H-1Gal), 4.10–3.98 (m, 2H, H-6aGal, H-6bGal), 3.91–3.80 (m, 3H,
H-4GlcN, H-5GlcN, H-5Gal), 3.75–3.73 (m, 1H, H-3Gal), 3.62 (d, 1H, J2,OH = 3.2 Hz, OH), 3.57–3.53 (m,

Molecules 2014, 19
422
1H, H-2Gal), 3.21 (d, 1H, J3,OH = 3.1 Hz, OH), 2.73–2.61 (m, 2H, SCH2CH3), 2.18–1.90 (4 s, 12H, Ac),
1.22 (t, 3H, SCH2CH3); 13C-NMR (125 MHz, CDCl3) δ 171.2, 170.9, 170.5, 170.0, 167.7, 167.4,
134.4, 134.2, 131.6, 131.2, 123.7, 123.6, 103.1, 81.1, 72.0, 71.9, 71.7, 71.0, 68.7, 63.1, 61.5, 53.9,
29.7, 29.2, 24.6, 21.0, 20.7, 20.7, 20.6, 14.9. HRMS (ESI) m/z: found [M+Na]+ 706.1776,
C30H37NO15S calcd for [M+Na]+ 706.1773.
AcO
TrocO
OAc
O AcO
NPhth
SEt
O
O
OH
OAc
Ethyl [4,6-di-O-acetyl-3-O-(2,2,2-trichloroethoxycarbonyl)-β-D-galactopyranosyl]-(1→4)-3,6-di-O-
acetyl-2-deoxy-2-phthalimide-1-thio-β-D-glucopyranoside (11). A solution of 10 (103 mg, 151 µmol)
and dibutyltin dichloride (4.6 mg, 15.1 µmol) in acetone (3.0 mL) was stirred for 10 min at rt. To the
solution were added PEMP (55 µL, 302 µmol) and TrocCl (27 µL, 196 µmol) at 10 °C. After stirring
for 20 min at the same temperature as the reaction was monitored by TLC (1:2 EtOAc–toluene, 1:1
CHCl3–acetone), the reaction was quenched by the addition of satd aq NH4Cl and concentrated. The
resulting residue was diluted with EtOAc and subsequently washed with H2O and brine. The organic
layer was dried over Na2SO4, filtered, concentrated. The resulting residue was purified by silica gel
column chromatography (2:7 EtOAc–toluene) to give 11 (108 mg, 84%). [α]D +30.0° (c 1.0, CHCl3);
1H-NMR (500 MHz, CDCl3) δ 7.88–7.74 (m, 4H, Phth), 5.70 (dd, 1H, J3,4 = 8.2 Hz, J2,3 = 10.6 Hz,
H-3GlcN), 5.49 (d, 1H, J1,2 = 10.6 Hz, H-1GlcN), 5.46 (d, 1H, J3,4 = 2.9 Hz, H-4Gal), 4.79 (m, 2H, H-3Gal,
OCH2CCl3), 4.65 (near dd, 1H, Jgem = 11.4 Hz, H-6aGlcN), 4.44 (d, 1H, J1,2 = 7.7 Hz, H-1Gal), 4.38 (dd,
1H, J5,6b = 4.2 Hz, H-6bGlcN), 4.31 (t, 1H, H-2GlcN), 4.11–4.03 (m, 2H, H-6aGal, H-6bGal), 3.91–3.77 (m,
4H, H-4GlcN, H-5GlcN, H-2Gal, H-5Gal), 3.47 (d, 1H, J2,OH = 5.2 Hz, OH), 2.72–2.62 (m, 2H, SCH2CH3),
2.14–1.91 (4 s, 12H, Ac), 1.22 (t, 3H, SCH2CH3); 13C-NMR (125 MHz, CDCl3) δ 171.2, 170.4, 170.2,
170.2, 167.8, 167.5, 153.2, 134.3, 134.3, 131.8, 131.3, 123.8, 103.3, 94.1, 81.2, 77.7, 77.3, 77.2, 72.2,
70.6, 69.2, 66.2, 63.1, 61.1, 54.0, 29.8, 24.6, 21.0, 20.7, 20.7, 20.6, 15.1. HRMS (ESI) m/z: found
[M+Na]+ 880.0823, C33H38Cl3NO17S calcd for [M+Na]+ 880.0818.
NPh
O
CF3
O
OPMB
OAc
AcO
3,4-Di-O-acetyl-2-O-p-methoxybenzyl-L-fucopyranosyl N-phenyl 2,2,2-trifluoroacetimidate (12). To a
solution of phenyl 3,4-di-O-acetyl-2-O-p-methoxybenzyl-1-thio-β-L-fucopyranoside [42] (1.21 g,
2.63 mmol) in acetone/H2O (13.1 mL, 96:4) was added NBS (701 mg, 3.94 mmol) at −15 °C. After
stirring for 1 h at the same temperature as the reaction was monitored by TLC (1:1 EtOAc–hexane),
the reaction was quenched by the addition of satd aq Na2S2O3 and then diluted with EtOAc, washed
with H2O and brine. The organic layer was dried over Na2SO4, filtered, concentrated. The resulting
residue was purified by silica gel column chromatography (2:3 EtOAc–hexane) to give the
corresponding hemiacetal product (969 mg, quant.), which was then dissolved in acetone (52.6 mL).
To the solution were added 2,2,2-trifluoro-N-phenylacetimidoyl chloride (853 µL, 5.26 mmol) and

Molecules 2014, 19
423
K2CO3 (1.82 g, 13.2 mmol) at rt. After stirring for 2.5 h at rt as the reaction was monitored by TLC
(1:2 EtOAc–hexane), the reaction mixture was filtered through Celite. The filtrate and washings were
concentrated. The resulting residue was purified by silica gel column chromatography (1:4 EtOAc–hexane)
to give 12 (1.33 g, 94%, α/β = 1/1). [α]D −81.6° (c 1.0, CHCl3); 13C-NMR (125 MHz, CDCl3) δ 170.3,
170.2, 169.9, 169.8, 159.4, 159.3, 143.5, 143.2, 129.8, 129.7, 129.5, 129.3, 129.1, 128.9, 128.8, 128.6,
128.6, 128.4, 128.4, 124.3, 124.2, 119.3, 119.2, 117.2, 114.9, 114.0, 113.7, 113.7, 97.0, 93.6, 77.6,
77.2, 74.9, 74.7, 72.9, 72.6, 72.2, 70.8, 70.2, 70.0, 69.7, 67.3, 55.2, 55.1, 20.7, 20.6, 20.5, 20.5, 15.9,
15.8. 1H-NMR (500 MHz, CDCl3) α-isomer: δ 7.45–6.71 (m, 9H, Ar), 6.46 (br s, 1H, H-1), 5.35–5.31
(m, 2H, H-3, H-4), 4.75–4.59 (m, 2H, OCH2Ar), 4.27 (br s, 1H, H-5), 3.95 (br d, 1H, H-2), 3.87–3.77
(m, 3H, OMe), 2.16–1.99 (m, 6H, Ac), 1.18–1.14 (m, 3H, H-6). β-isomer: δ 7.45–6.71 (m, 9H, Ar),
5.68 (br s, 1H, H-1), 5.20 (br s, 1H, H-4), 4.98 (br s, 1H, H-3) 4.75–4.59 (m, 2H, OCH2Ar), 3.87–3.77
(m, 5H, H-2, H-5, OMe), 2.16–1.99 (m, 6H, Ac), 1.18–1.14 (m, 3H, H-6). Possible other stereoisomers
were not assigned. HRMS (ESI) m/z: found [M+Na]+ 562.1657, C26H28F3NO8 calcd for [M+Na]+ 562.1659.
AcO
TrocO
OAc
O AcO
NPhth
SEt
O
O
O
OAc
O
OH
OAc
AcO
Ethyl (3,4-di-O-acetyl-α-L-fucopyranosyl)-(1→2)-[4,6-di-O-acetyl-3-O-(2,2,2-trichloroethoxycarbonyl)-β-
D-galactopyranosyl]-(1→4)-3,6-di-O-acetyl-2-deoxy-2-phthalimide-1-thio-β-D-glucopyranoside (14).
To a mixture of 11 (1.06 g, 1.24 mmol) and 12 (1.33 g, 2.47 mmol) in CPME/CH2Cl2 (1:1, 74.2 mL)
was added 4 Å molecular sieves AW-300 (7.42 g) at rt. After stirring for 30 min, the mixture was
cooled to −80 °C. TMSOTf (22 µL, 124 µmol) was then added to the mixture at −80 °C. After stirring
for 5.5 h at the same temperature as the reaction was monitored by TLC (1:2 EtOAc–toluene, 1:2
EtOAc–hexane) and MALDI-TOF MS, the reaction was quenched by the addition of satd aq NaHCO3.
The reaction mixture was diluted with CHCl3 and filtered through Celite. The filtrate was then washed
with satd aq NaHCO3 and H2O. The organic layer was subsequently dried over Na2SO4, and
concentrated. The resulting residue was purified by silica gel column chromatography (2:7 EtOAc–toluene)
to give 13 with unidentified impurity (1.66 g). The crude mixture was then dissolved in CH2Cl2 (44.6 mL).
To the solution was added trifluoroacetic acid (5.0 mL) at 0 °C. After stirring for 40 min at rt as the
reaction was monitored by TLC (1:1 EtOAc–hexane), the mixture was co-evaporated with toluene.
The residue was diluted with CHCl3 and subsequently washed with satd aq NaHCO3 and H2O. The
organic layer was dried over Na2SO4, filtered, concentrated. The resulting residue was purified by silica
gel column chromatography (1:2 EtOAc–toluene) to give 14 (1.18 g, 88% over two steps). [α]D −38.1°
(c 1.0, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.88–7.73 (m, 4H, Phth), 5.80 (t, 1H, J2,3 = J3,4 = 10.6 Hz,
H-3GlcN), 5.47–5.45 (m, 2H, H-1GlcN, H-4Gal), 5.29 (d, 1H, J1,2 = 2.5 Hz, H-1Fuc), 5.21 (d, 1H, J3,4 = 3.9 Hz,
H-4Fuc), 4.99 (dd, 1H, J2,3 = 10.7 Hz, H-3Fuc), 4.91 (dd, 1H, J3,4 = 3.6 Hz, J2,3 = 10.1 Hz, H-3Gal), 4.75
(s, 2H, OCH2CCl3), 4.51 (dd, 1H, J5,6a = 4.2 Hz, Jgem = 12.0 Hz, H-6aGlcN), 4.33–4.31 (m, 4H, H-2GlcN
,
H-6bGlcN, H-1Gal, H-5Fuc), 4.17–4.09 (m, 2H, H-6aGal, H-6bGal), 3.95–3.83 (m, 5H, H-4GlcN, H-5GlcN
,
H-2Gal, H-5Gal, H-2Fuc), 2.74–2.62 (m, 2H, SCH2CH3), 2.16–1.91 (6 s, 18H, Ac), 1.27–1.22 (m, 6H,

Molecules 2014, 19
424
13
H-6Fuc, SCH2CH3); C-NMR (125 MHz, CDCl3) δ 170.6, 170.5, 170.3, 169.9, 169.8, 167.5, 167.2,
152.8, 134.3, 134.2, 131.6, 131.2, 123.6, 100.1, 99.6, 93.8, 81.4, 77.8, 77.2, 74.9, 73.2, 71.2, 70.7,
70.6, 67.0, 66.6, 65.7, 62.5, 60.9, 53.9, 29.6, 24.8, 20.8, 20.7, 20.6, 20.6, 20.5, 20.4, 15.6, 15.0. HRMS
(ESI) m/z: found [M+Na]+ 1110.1609, C43H52Cl3NO23S calcd for [M+Na]+ 1110.1611.
AcO
TrocO
OAc
O AcO
NPhth
SEt
O
O
O
OAc
O
OAc
OAc
AcO
Ethyl (2,3,4-tri-O-acetyl-α-L-fucopyranosyl)-(1→2)-[4,6-di-O-acetyl-3-O-(2,2,2-trichloroethoxycarbonyl)-
β-D-galactopyranosyl]-(1→4)-3,6-di-O-acetyl-2-deoxy-2-phthalimide-1-thio-β-D-glucopyranoside
(15). To a solution of 14 (1.06 g, 975 µmol) in pyridine (4.9 mL) was added acetic anhydride (4.9 mL)
at 0 °C. After stirring for 2 h at rt as the reaction was monitored by TLC (1:1 EtOAc–hexane), the
reaction was quenched by addition of MeOH at 0 °C and then evaporated. The residue was diluted
with CHCl3, washed with 2 M HCl, H2O, satd aq NaHCO3, and brine, dried over Na2SO4, concentrated.
The residue obtained was purified by silica gel column chromatography (2:3 EtOAc–hexane) to give
15 (1.05 g, 95%). [α]D −39.6° (c 1.0, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.86–7.73 (m, 4H, Phth),
5.79 (t, 1H, J2,3 = J3,4 = 10.1 Hz, H-3GlcN), 5.47 (d, 1H, J1,2 = 10.6 Hz, H-1GlcN), 5.43 (d, 1H, J3,4 = 4.3 Hz,
H-4Gal), 5.39 (d, 1H, J1,2 = 3.8 Hz, H-1Fuc), 5.34 (d, 1H, J3,4 = 3.9 Hz, H-4Fuc), 5.16 (dd, 1H, J2,3 = 10.9 Hz,
H-3Fuc), 5.07 (dd, 1H, H-2Fuc), 4.88 (dd, 1H, J2,3 = 9.8 Hz, H-3Gal), 4.84 (d, 1H, Jgem = 11.7 Hz,
OCH2CCl3), 4.63 (d, 1H, OCH2CCl3), 4.51 (dd, 1H, J5,6a = 1.8 Hz, Jgem = 10.8 Hz, H-6aGlcN),
4.47–4.43 (m, 2H, H-1Gal, H-5Fuc), 4.39–4.30 (m, 2H, H-2GlcN, H-6bGlcN), 4.16 (dd, 1H, J5,6a = 6.6 Hz,
Jgem = 11.2 Hz, H-6aGal), 4.09 (dd, 1H, H-6bGal), 3.94 (t, 1H, H-4GlcN), 3.89–3.83 (m, 3H, H-5GlcN
,
H-2Gal, H-5Gal), 2.74–2.62 (m, 2H, SCH2CH3), 2.17–1.91 (7 s, 21H, Ac), 1.26–1.22 (m, 6H, H-6Fuc,
SCH2CH3); 13C-NMR (125 MHz, CDCl3) δ 170.6, 170.5, 170.3, 170.1, 169.9, 169.7, 169.7, 167.5,
167.2, 152.7, 134.3, 134.1, 131.6, 131.2, 123.6, 100.0, 96.2, 93.8, 81.4, 77.8, 77.2, 76.9, 74.7, 72.5,
71.1, 70.7, 70.6, 67.9, 67.7, 66.4, 65.3, 62.7, 60.9, 53.8, 29.6, 24.8, 20.8, 20.6, 20.6, 20.5, 20.3, 15.5,
15.1. HRMS (ESI) m/z: found [M+Na]+ 1152.1716, C45H54Cl3NO24S calcd for [M+Na]+ 1152.1714.
AcO
TrocO
OAc
O AcO
NPhth
O
NHCbz
O
O
O
OAc
O
OAc
OAc
AcO
5-Benzyloxycarbonylamino-1-pentyl (2,3,4-tri-O-acetyl-α-L-fucopyranosyl)-(1→2)-[4,6-di-O-acetyl-3-
O-(2,2,2-trichloroethoxycarbonyl)-β-D-galactopyranosyl]-(1→4)-3,6-di-O-acetyl-2-deoxy-2-
phthalimide-β-D-glucopyranoside (17). A mixture of 15 (372 mg, 329 µmol) and 16 (234 mg, 988 µmol),
and NIS (148 mg, 658 µmol) was exposed to high vacuum for 1 h. The mixture was dissolved in
CH2Cl2 (13.2 mL), to which 4 Å molecular sieves (1.32 g) was added at rt. After stirring for 30 min at

Molecules 2014, 19
425
rt and then for 10 min at 0 °C, TfOH (7.1 µL, 65.8 µmol) was added to the mixture. After stirring for
1 h at 0 °C as the reaction was monitored by TLC (1:1 EtOAc–hexane, 2:1 EtOAc–hexane), additional
portions of NIS (148 mg, 658 µmol) and TfOH (7.1 µL, 65.8 µmol) were added to the mixture. After 8 h
and 16 h, further portions of TfOH (7.1 µL of each) were added to the mixture and the stirring was
continued. After stirring for total 30 h, the reaction was quenched by the addition of satd aq NaHCO3.
The precipitate was filtered through Celite. The filtrate was diluted with CHCl3, washed with satd aq
Na2S2O3 and brine. The organic layer was subsequently dried over Na2SO4, concentrated and the
residue was then purified by silica gel column chromatography (1:1 EtOAc–hexane) and gel filtration
column chromatography (LH-20, 1:1 CHCl3–MeOH) to give 17 (375 mg, 87%). [α]D −41.1° (c 1.0,
CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.85–7.69 (m, 4H, Phth), 7.47–7.30 (m, 5H, Ph), 5.74 (dd, 1H,
J3,4 = 9.0 Hz, J2,3 = 10.8 Hz, H-3GlcN), 5.42 (d, 1H, J3,4 = 3.1 Hz, H-4Gal), 5.40 (d, 1H, J1,2 = 3.8 Hz,
H-1Fuc), 5.33 (d, 1H, J3,4 = 3.8 Hz, H-4Fuc), 5.31 (d, 1H, J1,2 = 8.5 Hz, H-1GlcN), 5.17 (dd, 1H, J2,3 = 10.9 Hz,
H-3Fuc), 5.07–5.04 (m, 3H, H-2Fuc, OCH2), 4.88 (dd, 1H, J2,3 = 9.8 Hz, H-3Gal), 4.84 (d, 1H, Jgem = 11.6 Hz,
OCH2), 4.64–4.62 (m, 2H, OCH2(CH2)3CH2NH, OCH2), 4.55 (dd, 1H, J5,6a = 1.8 Hz, Jgem = 12.1 Hz,
H-6aGlcN), 4.47–4.43 (m, 2H, H-1Gal, H-5Fuc), 4.37 (dd, 1H, J5,6b = 5.2 Hz, H-6bGlcN), 4.24 (dd, 1H,
H-2GlcN), 4.16 (dd, 1H, J5,6a = 6.7 Hz, Jgem = 11.2 Hz, H-6aGal), 4.09 (dd, 1H, H-6bGal), 3.94 (t, 1H,
H-4GlcN), 3.88–3.79 (m, 4H, H-5GlcN, H-2Gal, H-5Gal, OCH2(CH2)3CH2NH), 3.46–3.44 (m, 1H,
OCH2(CH2)3CH2NH), 2.95–2.91 (m, 2H, OCH2(CH2)3CH2NH), 2.17–1.91 (7 s, 21H, Ac), 1.51–1.11 (m,
13
9H, H-6Fuc, OCH2(CH2)3CH2NH); C-NMR (125 MHz, CDCl3) δ 170.7, 170.6, 170.3, 170.2, 170.0,
169.8, 156.2, 152.8, 136.7, 134.3, 128.5, 128.1, 128.1, 123.6, 100.1, 98.1, 96.2, 93.8, 77.6, 74.8, 72.9,
72.5, 71.1, 70.6, 70.6, 70.0, 69.8, 67.9, 67.8, 66.5, 66.4, 65.3, 62.3, 61.0, 54.7, 40.8, 29.3, 28.8, 23.0,
20.9, 20.7, 20.6, 20.6, 20.4, 15.5. HRMS (ESI) m/z: found [M+Na]+ 1327.2890, C56H67Cl3N2O27 calcd
for [M+Na]+ 1327.2889.
AcO
HO
OAc
O AcO
NPhth
O
NHCbz
O
5
O
O
OAc
O
OAc
OAc
AcO
5-Benzyloxycarbonylamino-1-pentyl (2,3,4-tri-O-acetyl-α-L-fucopyranosyl)-(1→2)-(4,6-di-O-acetyl-β-
D-galactopyranosyl)-(1→4)-3,6-di-O-acetyl-2-deoxy-2-phthalimide-β-D-glucopyranoside (18). To a
solution of 17 (289 mg, 215 µmol) in AcOH/(CH2Cl)2 (3:1, 14.3 mL) was added Zn powder (2.89 g) at
rt. The reaction mixture was stirred for 1 h at 40 °C as the reaction was monitored by TLC (3:1
EtOAc–hexane). The precipitate was filtered through Celite and the filtrate was co-evaporated with
toluene. The residue obtained was purified by silica gel column chromatography (3:1 EtOAc–hexane)
1
to give 18 (233 mg, 97%). [α]D −56.6° (c 1.0, CHCl3); H-NMR (500 MHz, CDCl3) δ 7.85–7.69 (m,
4H, Phth), 7.38–7.30 (m, 5H, Ph), 5.74 (dd, 1H, J3,4 = 9.0 Hz, J2,3 = 10.8 Hz, H-3GlcN), 5.39 (d, 1H,
J
3,4 = 3.6 Hz, H-4Gal), 5.33 (d, 1H, J3,4 = 3.8 Hz, H-4Fuc), 5.31 (d, 1H, J1,2 = 8.5 Hz, H-1GlcN), 5.26–5.23
(m, 2H, H-3Fuc, OCH2Ph), 5.16 (dd, 1H, J1,2 = 3.6 Hz, J2,3 = 9.9 Hz, H-2Fuc), 5.07 (m, 2H, H-1Fuc,
OCH2Ph), 4.65 (s, 1H, OCH2(CH2)3CH2NH), 4.51 (dd, 1H, J5,6a = 1.8 Hz, Jgem = 12.0 Hz, H-6aGlcN),
4.42–4.37 (m, 2H, H-6bGlcN, H-5Fuc), 4.31 (d, 1H, J1,2 = 7.7 Hz, H-1Gal), 4.23 (dd, 1H, H-2GlcN), 4.11

Molecules 2014, 19
426
(m, 2H, H-6aGal, H-6bGal), 3.92 (t, 1H, J4,5 = 9.0 Hz, H-4GlcN), 3.86–3.79 (m, 4H, H-5GlcN, H-3Gal,
H-5Gal, OCH2(CH2)3CH2NH), 3.54 (dd, 1H, J2,3 = 9.5 Hz, H-2Gal), 3.47–3.43 (m, 1H,
OCH2(CH2)3CH2NH), 2.94–2.90 (m, 2H, OCH2(CH2)3CH2NH), 2.18–1.91 (7 s, 21H, Ac), 1.49–1.11
(m, 9H, H-6Fuc, OCH2(CH2)3CH2NH); 13C-NMR (125 MHz, CDCl3) δ 171.0, 170.7, 170.7, 170.4,
170.1, 170.1, 169.9, 156.2, 136.6, 134.3, 131.4, 128.5, 128.0, 123.5, 100.1, 98.1, 97.8, 74.9, 73.0, 72.4,
71.1, 71.0, 69.9, 69.7, 69.6, 68.2, 67.7, 66.5, 65.2, 62.4, 61.5, 54.8, 40.8, 29.6, 29.3, 28.8, 23.0, 20.8,
20.7, 20.6, 20.6, 20.5, 15.7. HRMS (ESI) m/z: found [M+Na]+ 1153.3847, C53H66N2O25 calcd for
[M+Na]+ 1153.3851.
Si
O
O
O
BnO
SPh
OBz
Phenyl 2-O-benzoyl-3-O-benzyl-4,6-O-di-tert-butylsilylene-1-thio-β-D-galactopyranoside (20). To a
solution of Phenyl 3-O-benzyl-1-thio-β-D-galactopyranoside (262 mg, 724 µmol) in pyridine (7.2 mL)
was added di-tert-butylsilyl bis(trifluoromethanesulfonate) (260 µL, 796 µmol) at 0 °C. After stirring
for 3.5 h at 0 °C as the reaction was monitored by TLC (1:1 EtOAc–hexane), benzoic anhydride
(328 mg, 1.45 mmol) was added to the mixture at 0 °C. After stirring for 22 h at rt as the reaction was
monitored by TLC (1:3 EtOAc–hexane), the reaction was quenched by the addition of MeOH at 0 °C.
The mixture was co-evaporated with toluene. The residue obtained was diluted with EtOAc, washed
with 2 M HCl, H2O, satd aq NaHCO3, and brine, dried over Na2SO4, concentrated. The resulting
residue was purified by silica gel column chromatography (1:7 EtOAc–hexane) to give 20 (324 mg,
74%). [α]D +66.9° (c 0.6, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 8.06–7.16 (m, 15H, Ph), 5.70 (t, 1H,
J1,2 = J2,3 = 9.8 Hz, H-2), 4.79 (d, 1H, H-1), 4.72 (d, 1H, Jgem = 12.8 Hz, OCH2Ph), 4.60–4.57 (m, 2H,
H-4, OCH2Ph), 4.30–4.23 (m, 2H, H-6a, H-6b), 3.57 (dd, 1H, H-3), 3.40 (s, 1H, H-5), 1.16–1.08 (2 s,
13
18H, 2 t-Bu); C-NMR (125 MHz, CDCl3) δ 165.4, 137.9, 134.4, 133.0, 132.1, 130.1, 129.9, 128.8,
128.3, 127.6, 127.5, 87.6, 79.3, 75.1, 70.0, 69.8, 69.4, 67.3, 27.6, 23.4, 20.7. HRMS (ESI) m/z: found
[M+Na]+ 629.2363, C34H42O6SSi calcd for [M+Na]+ 629.2364.
Si
O
O
O
TrocO
AcO
OAc
O
NPhth
O
TrocHN
AcO
O
NHCbz
O
5
O
O
OAc
O
OAc
OAc
AcO
5-Benzyloxycarbonylamino-1-pentyl [2-deoxy-4,6-O-di-tert-butylsilylene-2-(2,2,2-trichloroethoxycarbamoyl)-
3-O-(2,2,2-trichloroethoxycarbonyl)-α-D-galactopyranosyl]-(1→3)-[2,3,4-tri-O-acetyl-α-L-fucopyranosyl-
(1→2)]-(4,6-di-O-acetyl-β-D-galactopyranosyl)-(1→4)-3,6-di-O-acetyl-2-deoxy-2-phthalimide-β-D-

Molecules 2014, 19
427
glucopyranoside (21). A mixture of 18 (103 mg, 91.1 µmol) and 19 (138 mg, 182 µmol), and NIS (46 mg,
364 µmol) was exposed to high vacuum for 1 h. The mixture was dissolved in CH2Cl2 (2.7 mL), to
which 4 Å molecular sieves (273 mg) was added at rt. After stirring for 30 min at rt and then for 10 min
at 0 °C, TfOH (1.9 µL, 18.2 µmol) was added to the mixture. After stirring for 3 h at 0 °C as the
reaction was monitored by TLC (3:1 EtOAc–hexane, 1:1 EtOAc–hexane, 1:3 EtOAc–hexane),
additional portions of NIS (23 mg) and TfOH (1.0 µL) were added to the mixture and the stirring was
continued. After stirring for total 5 h, the reaction was quenched by the addition of satd aq NaHCO3.
The precipitate was filtered through Celite. The filtrate was diluted with CHCl3, washed with satd aq
Na2S2O3 and brine. The organic layer was subsequently dried over Na2SO4, concentrated and the
residue was then purified by silica gel column chromatography (1:1 EtOAc–hexane) to give 21 (132 mg,
82%), and 9.5 mg (9%) of 18 was recovered. [α]D +23.8° (c 1.7, CHCl3); 1H-NMR (500 MHz, CD3CN)
δ 7.77–7.70 (m, 4H, Phth), 7.30–7.22 (m, 5H, Ph), 5.74 (d, 1H, JNH,2 = 9.7 Hz, NHGalN), 5.64 (dd, 1H,
J3,4 = 9.0 Hz, J2,3 = 11.9 Hz, H-3GlcN), 5.35 (d, 1H, J3,4 = 2.8 Hz, H-4Gal), 5.30 (m, 2H, H-1Fuc,
OCH2(CH2)3CH2NH), 5.24 (d, 1H, J3,4 = 2.3 Hz, H-4Fuc), 5.20 (d, 1H, J1,2 = 10.8 Hz, H-1GlcN), 5.08 (d,
1H, J1,2 = 4.0 Hz, H-1GalN), 5.07 (dd, 1H, J1,2 = 3.5 Hz, J2,3 = 11.0 Hz, H-2Fuc), 4.97 (dd, 1H, H-3Fuc),
4.93 (s, 2H, OCH2), 4.86–4.79 (m, 2H, OCH2), 4.78–4.68 (m, 3H, H-3GalN, H-4GalN, OCH2), 4.59 (d,
1H, Jgem = 12.3 Hz, OCH2), 4.41–4.28 (m, 6H, H-6aGlcN, H-1Gal, H-5Fuc, H-2GalN, H-6aGalN, H-6bGalN),
4.09–3.96 (m, 5H, H-2GlcN, H-4GlcN, H-6bGlcN, H-3Gal, H-6aGal), 3.92 (dd, 1H, J5,6b = 6.1 Hz, Jgem = 11.3 Hz,
H-6bGal), 3.80–3.75 (m, 3H, H-5GlcN, H-5Gal, H-5GalN), 3.65–3.61 (m, 2H, H-2Gal, OCH2(CH2)3CH2NH),
3.39–3.34 (m, 1H, OCH2(CH2)3CH2NH), 2.71–2.65 (m, 2H, OCH2(CH2)3CH2NH), 2.18–1.80 (7 s,
13
21H, Ac), 1.31–0.96 (m, 27H, H-6Fuc, 2 t-Bu, OCH2(CH2)3CH2NH); C-NMR (125 MHz, CD3CN) δ
171.6, 171.5, 171.3, 171.2, 171.1, 155.5, 154.2, 135.7, 132.3, 129.4, 128.8, 128.7, 118.6, 118.3, 101.2,
98.9, 97.5, 96.6, 95.5, 94.4, 94.4, 79.1, 77.5, 76.6, 75.2, 74.4, 74.1, 73.5, 71.9, 71.5, 71.3, 70.8, 70.4,
69.0, 68.9, 68.6, 67.3, 66.6, 66.5, 65.7, 63.2, 62.2, 55.5, 49.4, 41.3, 30.0, 29.5, 27.9, 27.8, 23.7, 23.7,
21.5, 21.3, 21.2, 21.1, 21.0, 21.0, 20.8, 16.1. HRMS (ESI) m/z: found [M+Na]+ 1802.3642,
C73H95Cl6N3O33Si calcd for [M+Na]+ 1802.3640.
Si
O
O
O
II
BnO
AcO
OAc
O
NPhth
O
BzO
AcO
I
O
NHCbz
O
5
O
O
OAc
O
OAc
OAc
AcO
5-Benzyloxycarbonylamino-1-pentyl (2-O-benzoyl-3-O-benzyl-4,6-O-di-tert-butylsilylene-α-D-galactopyranosyl)-
(1→3)-[2,3,4-tri-O-acetyl-α-L-fucopyranosyl-(1→2)]-(4,6-di-O-acetyl-β-D-galactopyranosyl)-(1→4)-
3,6-di-O-acetyl-2-deoxy-2-phthalimide-β-D-glucopyranoside (22). A mixture of 18 (49.7 mg, 44.0 µmol)
and 20 (53.3 mg, 87.9 µmol), and NIS (22.0 mg, 176 µmol) was exposed to high vacuum for 1 h. The
mixture was dissolved in CH2Cl2 (1.3 mL), to which 4 Å molecular sieves (132 mg) was added at rt.
After stirring for 30 min at rt and then for 10 min at 0 °C, TfOH (1.0 µL, 8.79 µmol) was added to the

Molecules 2014, 19
428
mixture. After stirring for 1.5 h at 0 °C as the reaction was monitored by TLC (3:1 EtOAc–hexane, 1:1
EtOAc–hexane, 1:3 EtOAc–hexane), additional portion of TfOH (1.0 µL) was added to the mixture
and the stirring was continued. After stirring for total 2 h, the reaction was quenched by the addition of
satd aq NaHCO3. The precipitate was filtered through Celite. The filtrate was diluted with CHCl3,
washed with satd aq Na2S2O3 and brine. The organic layer was subsequently dried over Na2SO4,
concentrated and the residue was then purified by silica gel column chromatography (7:8 EtOAc–hexane)
to give 22 (41.2 mg, 58%), and 10.8 mg (22%) of 18 was recovered. [α]D +43.5° (c 1.3, CHCl3);
1H-NMR (500 MHz, CDCl3) δ 7.96–7.21 (m, 19H, Ar), 5.70 (dd, 1H, J3,4 = 8.7 Hz, J2,3 = 10.9 Hz,
H-3GlcN), 5.64 (dd, 1H, J1,2 = 3.6 Hz, J2,3 = 10.4 Hz, H-2GalII), 5.52 (d, 1H, J3,4 = 2.3 Hz, H-4Fuc), 5.41–5.40
(m, 2H, H-4GalI, H-1GalII), 5.34–5.33 (m, 2H, H-1GlcN, H-1Fuc), 5.13–5.07 (m, 4H, H-2Fuc, H-3Fuc,
OCH2Ph), 4.83 (d, 1H, J3,4 = 2.1 Hz, H-4GalII), 4.75 (d, 1H, Jgem = 12.0 Hz, OCH2Ph), 4.63 (br s, 1H,
OCH2(CH2)3CH2NH), 4.54 (d, 1H, OCH2Ph), 4.47 (dd, 1H, J5,6a = 3.9 Hz, Jgem = 12.2 Hz, H-6aGlcN),
4.41 (d, 1H, H-6bGlcN), 4.37–4.19 (m, 5H, H-2GlcN, H-1GalI, H-6aGalI, H-6bGalI, H-5Fuc), 4.13 (dd, 1H,
J5,6a = 6.7 Hz, Jgem = 11.3 Hz, H-6aGalII), 3.98–3.90 (m, 3H, H-4GlcN, H-3GalII, H-6bGalII), 3.86–3.78 (m,
3H, H-5GlcN, H-3GalI, OCH2(CH2)3CH2NH), 3.69–3.63 (m, 3H, H-2GalI, H-5GalI, H-5GalII), 3.47–3.45 (m,
1H, OCH2(CH2)3CH2NH), 2.93–2.89 (m, 2H, OCH2(CH2)3CH2NH), 2.25–1.81 (6 s, 18H, Ac), 1.47–1.11
(m, 30H, H-6Fuc, 2 t-Bu, Ac, OCH2(CH2)3CH2NH); 13C-NMR (125 MHz, CDCl3) δ 170.6, 170.6,
170.4, 170.1, 170.0, 169.8, 169.2, 169.3, 165.7, 138.4, 136.6, 134.3, 133.0, 131.4, 130.2, 129.8, 128.5,
128.2, 128.1, 128.1, 127.5, 127.4, 123.5, 100.9, 98.1, 95.9, 92.7, 77.6, 74.3, 72.6, 71.1, 70.9, 70.3,
69.9, 69.7, 69.6, 68.6, 68.4, 68.1, 67.8, 66.8, 66.5, 65.4, 64.4, 62.3, 61.2, 54.6, 40.8, 29.7, 29.3, 28.8,
27.7, 27.3, 23.4, 23.0, 20.9, 20.8, 20.7, 20.6, 20.6, 19.5, 15.9. HRMS (ESI) m/z: found [M+Na]+
1649.6129, C81H102N2O31Si calcd for [M+Na]+ 1649.6128.
Si
O
O
O
HO
AcO
OAc
O
NPhth
O
AcHN
AcO
O
NHCbz
O
5
O
O
OAc
O
OAc
OAc
AcO
5-Benzyloxycarbonylamino-1-pentyl (2-acetamido-2-deoxy-4,6-O-di-tert-butylsilylene-α-D-galactopyranosyl)-
(1→3)-[2,3,4-tri-O-acetyl-α-L-fucopyranosyl-(1→2)]-(4,6-di-O-acetyl-β-D-galactopyranosyl)-(1→4)-
3,6-di-O-acetyl-2-deoxy-2-phthalimide-β-D-glucopyranoside (23). To a solution of 21 (45 mg, 25.2 µmol)
in CH2Cl2 (1.7 mL) were added AcOH (288 µL, 5.04 mmol) and Zn powder (225 mg, 3.44 mmol) at
rt. After stirring for 20 min at rt as the reaction was monitored by TLC (20:1 CHCl3–MeOH), another
portion of Zn powder (225 mg) was added to the mixture and the stirring was continued. After 30 min,
AcOH (288 µL) and CH2Cl2 (1.7 mL) were added to the mixture. After stirring for total 4 h, the
precipitate was filtered through Celite and the filtrate was washed with satd aq NaHCO3. The organic
layer was subsequently dried over Na2SO4, concentrated and the residue obtained was then dissolved
in CH2Cl2 (2.5 mL). To the mixture was added acetic anhydride (48 µL, 252 µmol) at 0 °C. After

Molecules 2014, 19
429
stirring for 1 h at rt as the reaction was monitored by TLC (2:1 CHCl3–acetone), the reaction mixture was
concentrated. The resulting residue was purified by silica gel column chromatography (2:1 CHCl3–acetone)
to give 23 (31 mg, 84%). [α]D +6.3° (c 0.6, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.85–7.70 (m, 4H,
Phth), 7.38–7.26 (m, 5H, Ph), 5.76–5.69 (m, 2H, H-3GlcN, NHGalN), 5.45–5.43 (m, 2H, H-4Gal, H-4Fuc),
5.36–5.31 (m, 2H, H-1GlcN, H-2Fuc), 5.15–5.07 (m, 5H, H-1Fuc, H-3Fuc, H-1GalN, OCH2), 4.63 (br s, 1H,
OCH2(CH2)3CH2NH), 4.50–4.43 (m, 4H, H-2GlcN, H-6aGlcN, H-6bGlcN, H-4GalN), 4.41–4.35 (m, 2H,
H-1Gal, H-5Fuc), 4.29 (d, 1H, Jgem = 11.2 Hz, H-6aGalN), 4.25–4.18 (m, 2H, H-2GalN, H-6bGalN), 4.10–4.04
(m, 2H, H-6aGal, H-6bGal), 3.95–3.92 (t, 1H, J3,4 = J4,5 = 9.9 Hz, H-4GlcN), 3.89–3.72 (m, 5H, H-5GlcN
,
H-2Gal, H-3Gal, H-5Gal, OCH2(CH2)3CH2NH), 3.56–3.45 (m, 3H, H-3GalN, H-5GalN, OCH2(CH2)3CH2NH),
2.94–2.90 (m, 2H, OCH2(CH2)3CH2NH), 2.60 (d, 1H, J3,OH = 11.5 Hz, OHGalN), 2.18–1.88 (8 s, 24H,
Ac), 1.51–1.05 (m, 27H, H-6Fuc, 2 t-Bu, OCH2(CH2)3CH2NH); 13C-NMR (125 MHz, CD3CN) δ 170.2,
170.2, 169.9, 169.9, 169.8, 169.7, 169.6, 155.9, 137.3, 134.4, 131.0, 128.1, 127.5, 127.4, 123.1, 117.0,
99.5, 97.6, 95.6, 93.4, 73.8, 73.6, 73.1, 72.6, 72.2, 70.8, 70.4, 69.8, 69.1, 67.8, 67.7, 67.6, 67.5, 66.3,
65.3, 64.8, 64.7, 61.7, 61.1, 54.2, 53.9, 48.6, 40.0, 30.9, 29.0, 28.7, 28.4, 28.3, 26.7, 26.4, 22.5, 22.4,
21.8, 20.2, 19.9, 19.9, 19.8, 19.7, 19.7, 19.6, 19.5, 14.7. HRMS (ESI) m/z: found [M+Na]+ 1496.5661,
C69H95N3O30Si calcd for [M+Na]+ 1496.5662.
AcO
AcO
OAc
O
AcO
OAc
O AcO
NPhth
O
AcHN
O
NHCbz
O
5
O
O
OAc
O
OAc
OAc
AcO
5-Benzyloxycarbonylamino-1-pentyl (2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranosyl)-
(1→3)-[2,3,4-tri-O-acetyl-α-L-fucopyranosyl-(1→2)]-(4,6-di-O-acetyl-β-D-galactopyranosyl)-(1→4)-
3,6-di-O-acetyl-2-deoxy-2-phthalimide-β-D-glucopyranoside (24). To a solution of 23 (31 mg, 21.2 µmol)
in THF (1.1 mL) was added TBAHF 1.0 M solution (212 µL) at rt. After stirring for 40 min at rt as the
reaction was monitored by TLC (10:1 CHCl3–MeOH), the reaction mixture was diluted with EtOAc
and washed with 2 M HCl, H2O, satd aq NaHCO3, and brine. The organic layer was then dried over
Na2SO4 and concentrated. The residue obtained was dissolved in pyridine (1.0 mL). To the mixture
was added acetic anhydride (1.0 mL) at 0 °C. After stirring for 21 h at rt as the reaction was monitored
by TLC (10:1 CHCl3–MeOH), the reaction was quenched by the addition of MeOH at 0 °C. The
mixture was co-evaporated with toluene. The residue was diluted with EtOAc and washed with 2 M
HCl, H2O, satd aq NaHCO3, and brine. The organic layer was then dried over Na2SO4 and
concentrated. The resulting residue was purified by silica gel column chromatography (10:10:1
CHCl3–toluene–MeOH) and gel filtration column chromatography (LH-20, 1:1 CHCl3–MeOH) to give
1
24 (30 mg, 98% over two steps). [α]D +2.6° (c 1.0, CHCl3); H-NMR (500 MHz, CDCl3) δ 7.85–7.70
(m, 4H, Phth), 7.38–7.26 (m, 5H, Ph), 6.32 (br d, 1H, J2,NH = 6.9 Hz, NHGalN), 5.76 (dd, 1H, J2,3 = 10.8 Hz,
J3,4 = 9.2 Hz, H-3GlcN), 5.50 (d, 1H, J1,2 = 3.7 Hz, H-1Fuc), 5.42 (d, 1H, J3,4 = 1.5 Hz, H-4GalN),
5.37–5.34 (m, 3H, H-4Gal, H-2Fuc, H-4Fuc), 5.31 (d, 1H, J1,2 = 8.5 Hz, H-1GlcN), 5.22 (d, 1H, J1,2 = 3.2 Hz,
H-1GalN), 5.13 (dd, 1H, J3,4 = 3.2 Hz, J2,3 = 11.0 Hz, H-3Fuc), 5.07 (s, 2H, OCH2Ph), 4.97 (dd, 1H,

Molecules 2014, 19
430
J2,3 = 11.3 Hz, H-3GalN), 4.66 (br s, 1H, OCH2(CH2)3CH2NH), 4.56–4.51 (m, 2H, H-6aGlcN, H-5Fuc),
4.48–4.43 (m, 1H, H-2GalN), 4.40–4.37 (m, 2H, H-6bGlcN, H-1Gal), 4.24 (dd, 1H, H-2GlcN), 4.17–4.14 (m,
2H, H-6aGal, H-6aGalN), 4.11–4.07 (m, 2H, H-6bGal, H-6bGalN), 4.03 (br d, 1H, H-5GalN), 3.96 (t, 1H,
J4,5 = 9.2 Hz, H-4GlcN), 3.86–3.74 (m, 5H, H-5GlcN, H-2Gal, H-3Gal, H-5Gal, OCH2(CH2)3CH2NH), 3.48–3.44
(m, 1H, OCH2(CH2)3CH2NH), 2.94–2.90 (m, 2H, OCH2(CH2)3CH2NH), 2.20–1.92 (11 s, 33H, Ac),
13
1.49–1.05 (m, 9H, H-6Fuc, OCH2(CH2)3CH2NH); C-NMR (125 MHz, CDCl3) δ 170.9, 170.6, 170.5,
170.4, 170.3, 170.0, 170.0, 169.9, 136.6, 134.3, 128.5, 128.1, 128.1, 123.6, 100.3, 98.1, 96.6, 77.6,
74.6, 74.5, 72.8, 71.2, 70.6, 69.9, 69.8, 68.6, 67.9, 67.4, 66.9, 66.7, 66.5, 65.3, 62.7, 62.2, 61.0, 54.7,
48.1, 40.8, 29.7, 29.3, 28.8, 23.0, 20.9, 20.7, 20.6, 20.6, 15.6. HRMS (ESI) m/z: found [M+Na]+
1482.4956, C67H85N3O33Si calcd for [M+Na]+ 1482.4958.
HO
HO
OH
O
HO
OH
O
NHAc
AcHN
HO
O
O
NHCbz
O
5
O
O
OH
O
OH
OH
HO
5-Benzyloxycarbonylamino-1-pentyl
(2-acetamido-2-deoxy-α-D-galactopyranosyl)-(1→3)-[α-L-
fucopyranosyl-(1→2)]-β-D-galactopyranosyl-(1→4)-2-acetamide-2-deoxy-β-D-glucopyranoside (25).
To a solution of 24 (19.8 mg, 13.6 µmol) in MeOH (1.4 mL) was added NaOMe (1M solution in
MeOH, 6.8 µL, 6.78 µmol) at 0 °C. After stirring for 4 h at rt as the reaction was monitored by TLC
(20:12:1 CHCl3–MeOH–H2O), the reaction was neutralized with Muromac (H+) resin. The resin was
filtered out and the filtrate was concentrated. The residue obtained was then dissolved in EtOH (2.8 mL).
To the solution was added NH2NH2·H2O (1.0 µL, 27.2 µmol) at rt. The reaction mixture was stirred at
reflux as monitored by TLC (5:4:1 CHCl3–MeOH–H2O). Additional portions of NH2NH2·H2O (2.0 µL)
was added to the mixture every 15 min (total amounts of NH2NH2·H2O added was 32 µL). After 6.5 h,
the reaction mixture was concentrated and exposed to high vacuum for 1 h. The resulting residue was then
dissolved in MeOH/CH2Cl2 (3:1, 4.4 mL). To the mixture was added acetic anhydride (26 µL, 272 µmol)
at 0 °C. After stirring for 1.5 h at rt as the reaction was monitored by TLC (5:4:1 CHCl3–MeOH–H2O),
the reaction mixture was concentrated. The residue obtained was purified by silica gel column
chromatography (Iatrobeads, 9:5:0.5 CHCl3–MeOH–H2O) to give 25 (10.3 mg, 80% over three steps).
1
[α]D +4.4° (c 0.3, MeOH); H-NMR (500 MHz, CD3OD) δ 7.45–7.43 (m, 5H, Ph), 5.36 (d, 1H,
J1,2 = 3.9 Hz, α-anomer H), 5.15 (d, 1H, J1,2 = 3.7 Hz, α-anomer H), 5.06 (s, 2H, OCH2Ph), 4.52 (d,
1H, J1,2 = 7.7 Hz, β-anomer H), 4.39 (d, 1H, J1,2 = 8.4 Hz, β-anomer H), 4.34–4.31 (m, 1H, H-5Fuc),
4.18–3.46 (m, 27H, ring H, OCH2(CH2)3CH2NH), 3.11–3.08 (m, 2H, OCH2(CH2)3CH2NH), 2.00–1.96
(2 s, 6H, Ac), 1.57–1.20 (m, 9H, H-6Fuc, OCH2(CH2)3CH2NH); 13C-NMR (125 MHz, CD3OD) δ
174.5, 173.5, 158.9, 138.5, 129.4, 128.9, 128.8, 102.8, 102.2, 100.3, 93.6, 78.5, 77.9, 77.2, 76.9, 74.2,
73.6, 73.5, 72.7, 71.9, 70.5, 70.5, 70.1, 69.9, 67.7, 67.3, 64.9, 63.4, 62.6, 61.8, 56.9, 51.3, 41.8, 30.5,
30.2, 24.3, 23.0, 22.7, 16.6. HRMS (ESI) m/z: found [M+Na]+ 974.3954, C41H65N3O22 calcd for
[M+Na]+ 974.3952.

Molecules 2014, 19
431
HO
HO
OH
O
HO
OH
O
NHAc
AcHN
HO
O
NH2
O
O
5
O
O
OH
O
OH
OH
HO
5-Amino-1-pentyl 2-acetamido-2-deoxy-α-D-galactopyranosyl-(1→3)-[α-L-fucopyranosyl-(1→2)]-β-D-
galactopyranosyl-(1→4)-2-acetamide-2-deoxy-β-D-glucopyranoside (1). To a solution of 25 (3.2 mg,
3.36 µmol) in MeOH/H2O (1:1, 3.2 mL) was added Pd/C (5 wt. %, 0.5 mg). After stirring for 3.5 h at rt
under a hydrogen atmosphere as the reaction was monitored by TLC (5:4:1:1 CHCl3–MeOH–H2O–AcOH),
additional portion of Pd/C (0.5 mg) was added to the mixture and the stirring was continued. After
12.5 h, further portion of Pd/C (0.5 mg) was added to the mixture. After stirring for total 21 h, the
mixture was filtered through membrane filter. The filtrate was concentrated and the residue obtained
was purified by gel filtration column chromatography (LH-20, MeOH) to give 1 (2.2 mg, 96%). [α]D
1
+4.4° (c 0.3, MeOH); H-NMR (500 MHz, D2O) δ 5.36 (d, 1H, J1,2 = 4.1 Hz, α-anomer H), 5.16 (d,
1H, J1,2 = 3.9 Hz, α-anomer H), 4.58 (d, 1H, J1,2 = 7.7 Hz, β-anomer H), 4.47 (d, 1H, J1,2 = 8.4 Hz,
β-anomer H), 4.31–4.29 (m, 1H, H-5Fuc), 4.23–3.56 (m, 27H, ring H, OCH2(CH2)3CH2NH), 2.98–2.95
(m, 2H, OCH2(CH2)3CH2NH), 2.02 (2 s, 6H, Ac), 1.67–1.22 (m, 9H, H-6Fuc, OCH2(CH2)3CH2NH);
13C-NMR (200 MHz, CD3OD) δ 174.4, 173.6, 103.0, 102.2, 100.3, 93.5, 78.3, 77.8, 77.1, 77.0, 74.1,
73.6, 73.5, 72.7, 71.9, 70.5, 70.3, 70.0, 69.9, 67.7, 64.8, 63.4, 62.6, 61.6, 56.8, 51.2, 40.7, 33.1, 30.8,
30.5, 29.8, 28.3, 24.2, 23.8, 23.0, 22.7, 16.6, 14.5. HRMS (ESI) m/z: found [M+Na]+ 840.3584,
C33H59N3O20 calcd for [M+Na]+ 840.3584
AcO
OAc
O
II
BnO
AcO
OAc
O
NPhth
O
BzO
AcO
I
O
NHCbz
O
5
O
O
OAc
O
OAc
OAc
AcO
5-Benzyloxycarbonylamino-1-pentyl (4,6-di-O-acetyl-2-O-benzoyl-3-O-benzyl-α-D-galactopyranosyl)-
(1→3)-[2,3,4-tri-O-acetyl-α-L-fucopyranosyl-(1→2)]-(4,6-di-O-acetyl-β-D-galactopyranosyl)-(1→4)-
3,6-di-O-acetyl-2-deoxy-2-phthalimide-β-D-glucopyranoside (26). Compound 22 (30.1 mg, 18.5 µmol)
was converted into 26 (23.6 mg, 81%) according to the procedure described for 24. [α]D +75.3° (c 0.2,
1
CHCl3); H-NMR (500 MHz, CDCl3) δ 7.96–7.16 (m, 19H, Ar), 5.75 (d, 1H, J3,4 = 1.9 Hz, H-4GalII),
5.72 (dd, 1H, J3,4 = 8.2 Hz, J2,3 = 8.8 Hz, H-3GlcN), 5.56 (d, 1H, J3,4 = 2.6 Hz, H-4Fuc), 5.42 (d, 1H,
J
1,2 = 3.9 Hz, H-1Fuc) 5.41 (d, 1H, J3,4 = 2.3 Hz, H-4GalI), 5.38–5.35 (m, 2H, H-1GalII, H-2GalII), 5.31 (d,
1H, J1,2 = 8.4 Hz, H-1GlcN), 5.22–5.17 (m, 2H, H-2Fuc, H-3Fuc), 5.07 (s, 2H, OCH2Ph), 4.70 (d, 1H,
Jgem = 11.8 Hz, OCH2Ph), 4.64 (br s, 1H, OCH2(CH2)3CH2NH), 4.49–4.40 (m, 4H, H-6aGlcN, H-6bGlcN
H-5Fuc, OCH2Ph), 4.30 (d, 1H, J1,2 = 7.4 Hz, H-1GalI), 4.23–4.13 (m, 4H, H-2GlcN, H-5GalII, H-6aGalII
H-6bGalII), 4.08 (dd, 1H, J3,4 = 3.2 Hz, J2,3 = 7.2 Hz, H-3GalII), 4.00 (dd, 1H, J5,6a = 6.7 Hz, Jgem = 11.3 Hz,
,
,

Molecules 2014, 19
432
H-6aGalI), 3.94–3.90 (m, 2H, H-4GlcN, H-6bGalI), 3.86–3.79 (m, 2H, H-5GlcN, OCH2(CH2)3CH2NH), 3.76
(dd, 1H, J2,3 = 7.4 Hz, J3,4 = 2.9 Hz, H-3GalI), 3.65 (t, 1H, H-2GalI), 3.57 (t, 1H, J5,6b = 6.7 Hz, H-5GalI),
3.48–3.43 (m, 1H, OCH2(CH2)3CH2NH), 2.93–2.89 (m, 2H, OCH2(CH2)3CH2NH), 2.24–1.83 (9 s,
27H, Ac), 1.47–1.09 (m, 9H, H-6Fuc, OCH2(CH2)3CH2NH); 13C-NMR (125 MHz, CDCl3) δ 170.6,
170.6, 170.5, 17.3, 170.2, 170.1, 169.9, 169.8, 169.4, 165.6, 156.2, 137.8, 136.6, 134.3, 133.3, 131.4,
129.9, 129.6, 128.5, 128.4, 128.2, 128.1, 128.1, 127.9, 127.5, 123.5, 100.5, 98.1, 96.1, 77.6, 74.2, 72.7,
71.4, 71.3, 70.9, 70.1, 69.8, 69.6, 68.0, 67.8, 67.7, 67.2, 66.5, 65.2, 62.5, 62.3, 61.2, 54.6, 40.8, 29.7,
29.3, 28.8, 23.0, 20.8, 20.8, 20.7, 20.7, 20.7, 20.6, 19.8, 15.8. HRMS (ESI) m/z: found [M+Na]+
1593.4316, C81H102N2O31Si calcd for [M+Na]+ 1593.4318.
HO
OH
O
II
BnO
HO
OH
O
NHAc
HO
HO
I
O
O
NHCbz
O
5
O
O
OH
O
OH
OH
HO
5-Benzyloxycarbonylamino-1-pentyl (3-O-benzyl-α-D-galactopyranosyl)-(1→3)-[α-L-fucopyranosyl-
(1→2)]-β-D-galactopyranosyl-(1→4)-2-acetamide-2-deoxy-β-D-glucopyranoside (27). Compound 26
(23.3 mg, 14.8 µmol) was converted into 27 (14.7 mg, 99%) according to the procedure described for
1
25. [α]D −6.2° (c 0.3, MeOH); H-NMR (500 MHz, CD3OD) δ 7.45–7.26 (m, 10H, Ph), 5.30 (near s,
1H, α-anomer H), 5.15 (d, 1H, J1,2 = 3.9 Hz, α-anomer H), 5.05 (s, 2H, OCH2Ph), 4.75 (d, 1H,
Jgem = 11.7 Hz, OCH2Ph), 4.64 (d, 1H, OCH2Ph), 4.53 (d, 1H, J1,2 = 7.5 Hz, β-anomer H), 4.38 (d, 1H,
J1,2 = 8.4 Hz, β-anomer H), 4.29–4.28 (m, 1H, H-5Fuc), 4.12–3.45 (m, 27H, ring H, OCH2(CH2)3CH2NH),
3.11–3.08 (m, 2H, OCH2(CH2)3CH2NH), 1.96 (s, 3H, Ac), 1.56–1.21 (m, 9H, H-6Fuc,
OCH2(CH2)3CH2NH); 13C-NMR (125 MHz, CD3OD) δ 173.5, 158.9, 139.9, 138.5, 129.4, 129.3,
129.1, 128.9, 128.8, 128.7, 102.8, 102.2, 100.2, 95.9, 79.5, 79.3, 78.6, 77.1, 76.7, 74.1, 73.6, 73.0,
72.6, 71.9, 70.5, 69.9, 69.1, 68.1, 67.6, 67.3, 65.6, 63.3, 62.6, 61.7, 56.7, 41.8, 30.5, 30.2, 24.3, 23.0,
16.6. HRMS (ESI) m/z: found [M+Na]+ 1023.4156, C46H68N2O22 calcd for [M+Na]+ 1023.4156.
HO
OH
O
II
HO
HO
OH
O
NHAc
HO
HO
I
O
O
NH2
O
5
O
O
OH
O
OH
OH
HO
5-Amino-1-pentyl
α-D-galactopyranosyl-(1→3)-[α-L-fucopyranosyl-(1→2)]-β-D-galactopyranosyl-
(1→4)-2-acetamide-2-deoxy-β-D-glucopyranoside (2). Compound 27 (2.1 mg, 2.10 µmol) was
converted into 2 (1.6 mg, quant.) according to the procedure described for 1, except for the use of a
mixed solvent (1:1, 1,4-dioxane–2% aq formic acid) as reaction media. [α]D +6.3° (c 0.3, MeOH);
1H-NMR (500 MHz, D2O) δ 5.31 (d, 1H, J1,2 = 4.1 Hz, α-anomer H), 5.22 (d, 1H, J1,2 = 2.5 Hz,

Molecules 2014, 19
433
α-anomer H), 4.59 (d, 1H, J1,2 = 7.6 Hz, β-anomer H), 4.46 (d, 1H, J1,2 = 8.4 Hz, β-anomer H), 4.30–3.42
(m, 28H, ring H, OCH2(CH2)3CH2NH), 2.98–2.95 (m, 2H, OCH2(CH2)3CH2NH), 2.01 (s, 3H, Ac),
1.67–1.21 (m, 9H, H-6Fuc, OCH2(CH2)3CH2NH); 13C-NMR (200 MHz, CD3OD) δ 173.5, 103.0, 102.2,
100.3, 96.2, 79.9, 78.5, 77.1, 76.7, 74.1, 73.8, 73.6, 73.2, 71.8, 71.4, 71.3, 70.3, 70.0, 69.9, 67.6, 65.8,
63.3, 62.6, 61.7, 56.7, 40.7, 29.8, 28.4, 24.2, 23.0, 16.5. HRMS (ESI) m/z: found [M+Na]+ 779.3320,
C31H56N2O20 calcd for [M+Na]+ 779.3319.
HO
HO
OH
O
NHAc
O
HO
NHCbz
O
5
O
O
OH
O
OH
OH
HO
5-Benzyloxycarbonylamino-1-pentyl
α-L-fucopyranosyl-(1→2)-β-D-galactopyranosyl-(1→4)-2-
acetamide-2-deoxy-β-D-glucopyranoside (28). Compound 18 (19.3 mg, 17.0 µmol) was converted into
28 (12.0 mg, 94%) according to the procedure described for 25. [α]D −110.0° (c 0.2, MeOH); 1H-NMR
(500 MHz, CD3OD) δ 7.34–7.28 (m, 5H, Ph), 5.22 (d, 1H, J1,2 = 3.1 Hz, α-anomer H), 5.05 (s, 2H,
OCH2Ph), 4.48 (d, 1H, J1,2 = 6.1 Hz, β-anomer H), 4.37 (d, 1H, J1,2 = 8.3 Hz, β-anomer H), 4.18–4.17
(m, 1H, H-5Fuc), 3.96–3.45 (m, 20H, ring H, OCH2(CH2)3CH2NH), 3.11–3.08 (m, 2H,
OCH2(CH2)3CH2NH), 1.96 (s, 3H, Ac), 1.57–1.20 (m, 9H, H-6Fuc, OCH2(CH2)3CH2NH); 13C-NMR
(125 MHz, CD3OD) δ 173.5, 158.9, 138.5, 129.4, 128.9, 128.8, 102.8, 102.5, 101.8, 79.0, 78.2, 77.1,
77.0, 76.9, 75.3, 74.1, 73.6, 71.7, 70.7, 70.5, 68.3, 67.3, 62.6, 61.6, 56.7, 41.8, 30.5, 30.2, 24.3, 23.0,
16.7. HRMS (ESI) m/z: found [M+Na]+ 771.3156, C33H52N2O17 calcd for [M+Na]+ 771.3158.
HO
HO
OH
O
NHAc
HO
O
NH2
O
5
O
O
OH
O
OH
OH
HO
5-Amino-1-pentyl α-L-fucopyranosyl-(1→2)-β-D-galactopyranosyl-(1→4)-2-acetamide-2-deoxy-β-D-
glucopyranoside (3). Compound 28 (5.9 mg, 7.88 µmol) was converted into 3 (3.5 mg, 73%)
1
according to the procedure described for 1. [α]D −76.3° (c 0.2, MeOH); H-NMR (500 MHz, D2O) δ
5.29 (d, 1H, J1,2 = 3.1 Hz, α-anomer H), 4.52 (d, 1H, J1,2 = 7.8 Hz, β-anomer H), 4.48 (d, 1H, J1,2 = 8.2 Hz,
β-anomer H), 4.22–4.20 (m, 1H, H-5Fuc), 3.98–3.42 (m, 18H, ring H, OCH2(CH2)3CH2NH), 2.98–2.95
(m, 2H, OCH2(CH2)3CH2NH), 2.02 (s, 3H, Ac), 1.69–1.21 (m, 9H, H-6Fuc, OCH2(CH2)3CH2NH);
13C-NMR (200 MHz, CD3OD) δ 173.6, 103.0, 102.5, 101.8, 79.0, 78.0, 77.1, 76.9, 75.2, 74.1, 73.6,
71.7, 70.7, 70.7, 70.2, 68.3, 62.7, 61.5, 56.6, 40.6, 39.5, 29.8, 28.2, 24.1, 23.0, 16.8. HRMS (ESI) m/z:
found [M+Na]+ 637.2791, C25H46N2O15 calcd for [M+Na]+ 637.2790.

Molecules 2014, 19
434
4. Conclusions
We have developed a novel approach to synthesizing human histo-blood group type 2 antigens. A
lactosamine derivative served as a key building block and was efficiently prepared from lactulose via
the Heyns rearrangement, a strategy that allowed us to lower the overall number of reaction steps.
The introduction of galactosamine and galactose in α-linked form into the O-antigen trisaccharide
was accomplished by a unique DTBS-directed α-glycosylation to afford type 2 A- and B-antigen
tetrasaccharides, respectively. The present synthetic protocol can provide rapid access to various
biologically relevant glycoconjugates that contain N-acetyl-lactosamine and ABO blood group
antigens. Studies on biological applications using the synthesized antigens will be reported in due course.
Acknowledgments
The iCeMS is supported by World Premier International Research Center Initiative (WPI), MEXT,
Japan. This work was financially supported in part by MEXT of Japan (a Grant-in-Aid for Scientific
Research (B) No. 22380067 to M.K.). We thank Kiyoko Ito (Gifu University) for providing technical
assistance and Yuji O. Kamatari (Division of Instrumental Analysis, Life Science Research Center,
Gifu University) for providing technical assistance of NMR mesurement (Bruker Biospin AVANCE
III 800).
Conflicts of Interest
The authors declare no conflict of interest.
References and Notes
1. Stanley, P.; Cummings, R.D. Structures Common to Different Glycans. In Essentials of
Glycobiology, 2nd ed.; Varki, A., Cummings, R.D., Esko, J.D., Freeze, H.H., Stanley, P.,
Bertozzi, C.R., Hart, G.W., Etzler, M.E., Eds.; Cold Spring Harbor: New York, NY, USA, 2009;
Chapter 13, pp. 175–198.
2. Ravn, V.; Dabelsteen, E. Tissue distribution of histo-blood group antigens. APMIS 2000, 108, 1–28.
3. Mollicone, R.; Gibaud, A.; Francois, A.; Ratcliffe, M.; Oriol, R. Acceptor specificity and tissue
distribution of three human α-3-fucosyltransferases. Eur. J. Biochem. 1990, 191, 169–176.
4. Meloncelli, P.; Lowary, T.L. Synthesis of ABO histo-blood group type I and II antigens.
Carbohydr. Res. 2010, 345, 2305–2322.
5. Landsteiner, K. Cell Antigens. In The Specificity of Serological Reactions; Landsteiner, K., Ed.;
Dover Publications, Inc.: New York, NY, USA, 1936; pp. 75–126.
6. Williamson, L.M.; Lowe, S.; Love, E.M.; Cohen, H.; Soldan, K.; McClelland, D.B.L.; Skacel, P.;
Barbara, J.A.J. Serious hazards of transfusion (SHOT) initiative: Analysis of the first two annual
reports. BMJ 1999, 319, 16–19.
7. Cooper, D.K.C. Xenoantigens and xenoantibodies. Xenotransplantation 1998, 5, 6–17.
8. Reid, M.E.; Bird, G.W.G. Associations between human red cell blood group antigens and disease.
Transfus. Med. Rev. 1990, 4, 47–55.
9. Anstee, D.J. The relationship between blood groups and disease. Blood 2010, 115, 4635–4643.

Molecules 2014, 19
435
10. O’Donnell, J.; Laffan, M.A. The relationship between ABO histo-blood group, factor VIII and
von Willebrand factor. Transfus. Med. 2001, 11, 343–351.
11. Ruiz-Palacios, G.M.; Cervantes, L.E.; Ramos, P.; Chavez-Munguia, B.; Newburg, D.S.
Campylobacter jejuni binds intestinal H(O) antigen (Fucα1,2Galβ1,4GlcNAc), and
fucosyloligosaccharides of human milk inhibit its binding and infection. J. Biol. Chem. 2003, 278,
14112–14120.
12. Rossez, Y.; Maes, E.; Darroman, T.L.; Gosset, P.; Ecobichon, C.; Curt, M.J.C.; Boneca, I.G.;
Michalski, J.-C.; Robbe-Masselot, C. Almost all human gastric mucin O-glycans harbor blood
group A, B or H antigens and are potential binding sites for Helicobacter pylori. Glycobiology
2012, 22, 1193–1206.
13. Lindesmith, L.; Moe, C.; Marionneau, S.; Ruvoen, N.; Jiang, X.; Lindblad, L.; Stewart, P.;
LePendu, J.; Baric, R. Human susceptibility and resistance to Norwalk virus infection. Nat. Med.
2003, 9, 548–553.
14. Tan, M.; Jiang, X. Norovirus and its histo-blood group antigen receptors: An answer to a
historical puzzle. Trends Microbiol. 2005, 13, 285–293.
15. Glinsky, G.V.; Ivanova, A.B.; Welsh, J.; McClelland, M. The role of blood group antigens in
malignant progression, Apoptosis resistance, and metastatic behavior. Transfus. Med. Rev. 2000,
14, 326–350.
16. Pinho, S.S.; Carvalho, S.; Marcos-Pinto, R.; Magalhães, A.; Oliveira, C.; Gu, J.; Dinis-Ribeiro, M.;
Carneiro, F.; Seruca, R.; Reis, C.A. Gastric cancer: Adding glycosylation to the equation. Trends
Mol. Med. 2013, 19, 664–676.
17. Paulsen, H.; Kolář, Č. Synthesis of the tetrasaccharide chains of the determinants of blood group
substances A and B. Angew. Chem. Int. Ed. 1978, 17, 771.
18. Korchagina, E.Y.; Ryzhov, I.M.; Byrgazov, K.A.; Popova, I.S.; Pokrovsky, S.N.; Bovin, N.V.
Block synthesis of blood group tetrasaccharides B (types 1, 3 and 4). Mendeleev Commun. 2009,
19, 152–154.
19. Ryzhov, I.M.; Korchagina, E.Y.; Popova, I.S.; Bovin, N.V. Block synthesis of A tetrasaccharides
(types 1, 3 and 4) related to the human ABO blood group system. Carbohydr. Res. 2012, 351, 17–25.
20. Zimmermann, P.; Greilich, U.; Schmidt, R.R. Total synthesis of a hexaosyl ceramide glycolipid
acting as a receptor for macrophage migration inhibiton-factor. Tetrahedron Lett. 1990, 31, 1849–1852.
21. Udodong, U.E.; Rao, C.S.; Fraser-Reid, B. n-Pentenyl glycosides in the efficient assembly of the
blood group substance B tetrasaccahride. Tetrahedron 1992, 48, 4713–4724.
22. Deshpande, P.P.; Kim, H.M.; Zatorski, A.; Park, T.-K.; Ragupathi, G.; Livingston, P.O.; Live, D.;
Danishefsky, S.J. Strategy in oligosaccharide synthesis: An application to a concise total synthesis
of the KH-1 (adenocarcinoma) antigen. J. Am. Chem. Soc. 1998, 120, 1600–1614.
23. Bovin, N.V.; Zurabyan, S.É.; Khorlin, A.Y. Stereoselectivity in glycosylation by means of
2-azido-2-desoxy-D-galactopyranose derivatives and the synthesis of the determinative
oligosaccharide of blood group A, type 1. Russ. Chem. Bull. 1982, 31, 1023–1030.
24. Paulsen, H.; Kolář, Č. Synthese der tetrasaccharid-ketten der type 2 der determinanten der
blutgruppensubstanzen A und B. Tetrahedron Lett. 1979, 31, 2882–2884.

Molecules 2014, 19
436
25. Milat, M.-L.; Sinäy, P. Synthesis of the tetrasaccharide O-α-L-fucopyranosyl-(12)-[O-α-D-
galactopyranosyl-(13)]-O-β-D-galactopyranosyl-(14)-2-acetamido-2-deoxy-D-glucopyranose,
the antigenic determinant of human blood-group B (type 2). Carbohydr. Res. 1981, 92, 183–189.
26. Pazynina, G.V.; Tyrtysh, T.V.; Bovin, N.V. Synthesis of histo blood-group antigens A and B
(type 2), xenoantigen Galα1-3Galβ1-4GlcNAc and related type 2 backbone oligosaccharides as
haptens in spacered form. Mendeleev Commun. 2002, 12, 143–145.
27. Lemieux, R.U.; Driquez, H. Chemical synthesis of 2-O-(α-L-fucopyranosyl)-3-O-(α-D-
galactopyranosyl)-D-galactose. Terminal structure of the blood-group B antigenic determinant.
J. Am. Chem. Soc. 1975, 97, 4069–4075.
28. Lemieux, R.U.; Bock, K.; Delbaere, L.T.J.; Koto, S.; Rao, V.S. The conformations of
oligosaccharides related to the ABH and Lewis human blood determinants. Can. J. Chem. 1980,
58, 631–653.
29. Lemieux, R.U.; Abbas, S.Z.; Burzynska, M.H.; Ratcliffe, R.M. Syntheses of derivatives of
N-acetyl-D-lactosamine from D-lactal hexaacetate. Hexa-O-acetyl-2-deoxy-2-phthalimide-β-D-
lactosyl chloride. Can. J. Chem. 1982, 60, 63–67.
30. Lemieux, R.U.; Abbas, S.Z.; Chung, B.Y. Syntheses of core chain trisaccharides related to human
blood group antigenic determinants. Can. J. Chem. 1982, 60, 68–75.
31. Hindsgaul, O.; Norberg, T.; le Pendu, J.; Lemieux, R.U. Synthesis of type 2 human blood-group
antigenic determinants. The H, X, and Y haptens and variations of the H type 2 determinant as
probes for the combining site of the lectin I of Ulex europaeus. Carbohydr. Res. 1982, 109, 109–142.
32. Heyns, K.; Meinecke K.-H. Über bildung und darstellung von d-glucosamin aus fructose und
ammoniak. Chem. Ber. 1953, 86, 1453–1462.
33. Wrodnigg, T.M.; Stütz, A.E. The Heyns rearrangement revisited: An exceptionally simple two-step
chemical synthesis of D-lactosamine from lactulose. Angew. Chem. Int. Ed. 1999, 38, 827–828.
34. Stütz, A.E.; Dekany, G.; Eder, B.; Illaszewicz, C.; Wrodnigg, T.M. An exceptionally simple
chemical synthesis of O-glycosylated D-glucosamine derivatives by Heyns rearrangement of the
corresponding O-glycosyl fructoses. J. Carbohydr. Chem. 2003, 22, 253–265.
35. Shan, Y.; Oulaidi, F.; Lahmann, M. Lactosamine from lactulose via the Heyns arrangement: A
practical protocol. Tetrahedron Lett. 2013, 54, 3960–3961.
36. Ohmae, M.; Takada, J.; Murakami, H.; Kimura, S. Rapid access to an orthogonally protected
Lewis X derivative: An important building block for synthesis of Lewis antigens. Chem. Lett.
2011, 40, 438–439.
37. Depré, D.; Düffels, A.; Green, L.G.; Lenz, R.; Ley, S.V.; Wong, C.-H. Synthesis of glycans from
the glycodelins: Two undeca-, two deca-, three nona-, an octa- and a heptasaccharide. Chem. Eur.
J. 1999, 5, 3326–3340.
38. Hense, A.; Ley, S.V.; Osborn, H.M.I.; Owen, D.R.; Poisson, J.-F.; Warriner, S.L.; Wesson, K.E.
Direct preparation of diacetals from 1,2-diketones and their use as 1,2-diol protecting groups.
J. Chem. Soc. Perkin Trans. 1 1997, 2023–2031, doi:10.1039/A702497E.
39. Muramatsu, W. Chemo- and regioselective monosulfonylation of nonprotected carbohydrates
catalyzed by organotin dichloride under mild conditions. J. Org. Chem. 2012, 77, 8083–8091.
40. Yu, B.; Tao, H. Glycosyl trifluoroacetimidates. Part 1: Preparation and application as new
glycosyl donors. Tetrahedron Lett. 2001, 42, 2405–2407.

Molecules 2014, 19
437
41. Yu, B.; Sun, J. Glycosylation with glycosyl N-phenyltrifluoroacetimidates (PTFAI) and a
perspective of the future development of new glycosylation methods. Chem. Commun. 2010, 46,
4668–4679.
42. Iwayama, Y.; Ando, H.; Tanaka, H.; Ishida, H.; Kiso, M. Synthesis of the glycan moiety of
ganglioside HPG-7 with an usual trimer of sialic acid as the inner sugar residue. Chem. Commun.
2011, 47, 9726–9728. The synthetic procedure for compound 12 derived from the known fucose
derivative in this literature was described in the Experimental Section.
43. Ishiwata, A.; Munemura, Y.; Ito, Y. Synergistic solvent effect in 1,2-cis-glycoside formation.
Tetrahedron 2008, 64, 92–102.
44. Konradsson, P.; Mootoo, D.R.; McDevitt, R.E.; Fraser-Reid, B. Iodonium ion generated in situ
from N-iodosuccimide and trifluoromethanesulphonic acid promotes direct linkage of ‘disarmed’
pent-4-enyl glycosides. J. Chem. Soc. Chem. Commun. 1990, 270–272.
45. Veeneman, G.H.; van Leeuwen, S.H.; van Boom, J.H. Iodonium ion promoted reactions at the
anomeric centre. II An efficient thioglycoside mediated approach toward the formation of
1,2-trans linked glycosides and glycosidic esters. Tetrahedron Lett. 1990, 31, 1331–1334.
46. Imamura, A.; Ando, H.; Ishida, H.; Kiso, M. Ganglioside GQ1b: Efficient total synthesis and the
expansion to synthetic derivatives to elucidate its biological roles. J. Org. Chem. 2009, 74,
3009–3023.
47. Demchenko, A.V. 1,2-cis O-Glycosylation: Methods, strategies, principles. Curr. Org. Chem.
2003, 7, 35–79.
48. Imamura, A.; Ando, H.; Korogi, S.; Tanabe, G.; Muraoka, O.; Ishida, H.; Kiso, M.
Di-tert-butylsilylene (DTBS) group-directed α-selective galactosylation unaffected by C-2
participating functionalities. Tetrahedron Lett. 2003, 44, 6725–6728.
49. Imamura, A.; Kimura, A.; Ando, H.; Ishida, H.; Kiso, M. Extended applications of
di-tert-butylsilylene-directed α-predominant galactosylation compatible with C2-participating
groups toward the assembly of various glycosides. Chem. Eur. J. 2006, 12, 8862–8870.
50. Imamura, A.; Ando, H.; Ishida, H.; Kiso, M. DTBS(di-tert-butylsilylene)-directed α-galactosylation
for the synthesis of biologically relevant glycans. Curr. Org. Chem. 2008, 12, 675–689.
51. Imamura, A.; Ando, H.; Ishida, H.; Kiso, M. DTBS effect: The unique sterically driven director
for α-galactosylation. Heterocycles 2008, 76, 883–908.
52. The synthetic procedure for compound 20 was described in the Experimental Section.
53. Furusawa, K. Removal of cyclic di-t-butylsilanediyl protecting groups using tributylamine
hydrofluoride (TBAHF) reagent. Chem. Lett. 1989, 509–510.
54. Malet, C.; Hindsgaul, O. Generation of molecular diversity on N-acetyllactosamine via
O-cyanomethyl ethers. Carbohydr. Res. 1997, 303, 51–65.
Sample Availability: Not available.
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).